Labcorp closes $375 million deal with 4.8% upside to target
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Labcorp Holdings has returned 80.6% to shareholders over three years and recently completed a US$375 million acquisition of Millennium Health, expanding its toxicology testing capabilities. The stock trades at a P/E of 30.0x, above the healthcare sector average, which analysts say matches its growth drivers and risk profile. Recent insider share sales raise questions about management's actions.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.